Management of Borderline Resectable Pancreatic Adenocarcinoma
Abstract
Pancreatic adenocarcinoma is the fourth most common cause of cancer-related death among U.S. men and women. Despite much effort in translational research, pancreatic adenocarcinoma remains a challenging disease with an overall 5-year survival rate less than 5%. To date, the only potentially curative treatment for managing pancreatic adenocarcinoma is surgical resection. However, more than 80% of patients are deemed either unresectable or metastatic upon diagnosis. For borderline resectable disease, although there is no high-level evidence supporting its use, an initial approach involving neoadjuvant therapy is preferred, as opposed to immediate surgery. In this year’s ASCO Gastrointestinal Cancers Symposium, several studies were presented with approaches towards treating borderline resectable pancreatic adenocarcinoma. Retrospective studies (Abstract #280, #304, #327) were presented and showed that neoadjuvant chemoradiation were associated with higher rates of negative margin resection and better survival. The tolerability of accelerated fraction radiotherapy with concomitant capecitabine was demonstrated in a phase I study (Abstract #329). More effective therapeutic approaches and prospective studies are needed for this devastating illness. This highlight article will focus on the management of borderline resectable pancreatic adenocarcinoma.
Downloads
References
Siegel, R., et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61(4): p. 212-36.
Jemal, A., et al. Cancer statistics, 2009. CA Cancer J Clin, 2009. 59(4): p. 225-49.
Li, D., et al. Pancreatic cancer. Lancet, 2004. 363(9414): p. 1049-57.
Callery, M.P., et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol, 2009. 16(7): p. 1727-33.
Hassan, M.M., et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol, 2007. 102(12): p. 2696-707.
Arnold, L.D., et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev, 2009. 18(9): p. 2397-405.
Jemal, A., et al., Cancer statistics, 2010. CA Cancer J Clin. 60(5): p. 277-300.
Lynch, S.M., et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol, 2009. 170(4): p. 403-13.
Jose mario Pimiento, T.H., Jill M. Weber, Manish Patel, Pamela Joy Hodul, Michael Chuong, Gregory Springett, et al. Multimodality therapy for borderline resectable pancreatic cancer: A single-institution experience. J Clin Oncol 2012. supple 4; abstr 280.
Pavlos Papavasiliou, J.R.P., Rodrigo Arrangoiz, Kathryn T Chen, Fang Zhu, Yun Shin Chun, John Parker Hoffman. Margin status and neoadjuvant chemoradiation in patients with borderline resectable pancreatic cancer. J Clin Oncol 2012. 30(suppl 4; abstr 304).
Jonathan Ben Ashman, A.A.M., Matthew D. Callister, Kunam S Reddy, David C Mulligan, Leonard L. Gunderson, Mitesh J. Borad neoadjuvant chemoradiation and intraoperative electron irradiation for locally unresectable/borderline resectable pancreas adenocarcinoma. J Clin Oncol 2012. 30(suppl 4; abstr 327).
Samhita Chakraborty, T.W.B., Monica M Morris, Erin Yarde, J Thomas Parsons, Reid B Adams, Hanna Kelly Sanoff. Accelerated fraction radiotherapy with concomitant capecitabine as neoadjuvant therapy of borderline resectable pancreatic cancer. J Clin Oncol 2012. 30(suppl 4; abstr 329).
National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (Version 2.2012). In: NCCN Clinical Practice Guidelines in Oncology.
Laurence, J.M., et al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg 15(11): p. 2059-69.
McClaine, R.J., et al. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford). 12(1): p. 73-9.
Stokes, J.B., et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 18(3): p. 619-27.

Copyright (c) 2014 Yuxia Jia, Tony JC Wang, John Allendorf, Muhammad Wasif Saif

This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.